中源協和(600645.SH)擬0元收購中源維康46.44%股權
格隆匯5月7日丨中源協和(600645.SH)公佈,公司擬收購天津慕紅信息科技合夥企業(有限合夥)(以下簡稱“天津慕紅”)持有的公司參股子公司北京中源維康基因科技有限公司(以下簡稱“中源維康”)15.72%股權,收購嘉興同卓股權投資合夥企業(有限合夥)(以下簡稱“嘉興同卓”)持有的中源維康30.72%股權,交易價格均為0元。同時,鑑於中源維康截止2019年12月31日經審計淨資產為人民幣-1014.77萬元,天津慕紅向公司支付本次標的股權轉讓的補償款人民幣747.6萬元。
中源維康自2018年成立以來,致力於腫瘤靶向藥物基因檢測產品的開發與研究,由於研發投入較大,目前原股東因無法保持持續的資金投入,擬轉讓其持有的股權。鑑於中源維康已完成基於Agena公司核酸質譜平台的腫瘤靶向藥物基因檢測系列產品的開發,與公司業務具有協同效應,試劑盒註冊報批完成後,可藉助公司下屬公司北京中杉金橋生物技術有限公司(以下簡稱“中杉金橋”)的病理診斷業務渠道,快速實現銷售收入;同時天津慕紅向公司支付本次標的股權轉讓的補償款747.6萬元。在參考信永中和會計師事務所出具的審計報告的基礎上,經各方友好協商,確定本次交易價格為0元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.